The specificity for early diagnostic of prostate-specific antigen (PSA) is low because the current technology mostly allows the detection of only one biomarker at one time. In this work, a dual- The proposed method presented the sensitivity of 0.03 ng ml −1 and 0.05 ng ml −1 for FPSA and TPSA respectively, with low cross-reactivities. Compared with the results from commercial chemiluminescent kits there was good correlation, indicating that this established method could be used to simultaneously to measure the concentrations of FPSA and TPSA in one serum sample and also could greatly facilitate the early diagnosis for PCa in clinical practice. KEYWORDS chemiluminescent enzyme immunoassay (CLEIA), dual-labeled, free prostate specific antigen (FPSA), simultaneous measurement, total prostate specific antigen (TPSA)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.